HOME >> BIOLOGY >> NEWS
PATH Malaria Vaccine Initiative announces partnership to develop novel malaria vaccine

Bethesda, MD, USA (December 14, 2006) In a move that promises to expand the types of malaria vaccine candidates in clinical development, the PATH Malaria Vaccine Initiative (MVI) today announced a new partnership with Sanaria Inc., a Maryland company, to accelerate development of a unique malaria vaccine candidate.

Supported by a $29.3 million grant to PATH from the Bill & Melinda Gates Foundation, this strategic partnership will focus on the development and manufacture of Sanaria's malaria vaccine candidateone that uses a novel, whole-parasite approach to preventing infection from the most deadly malaria parasite, Plasmodium falciparum. MVI and Sanaria will move quickly to conduct an initial safety and test-of-concept trial of the Sanaria candidate among volunteers in the United States.

"Close to one million children die of malaria each year," said Dr. Melinda Moree, Director of MVI. "With this support, we can examine another promising malaria vaccine technology and bring the field closer to delivering a safe, effective, and affordable pediatric malaria vaccine to at-risk communities in Africa."

Of the more than one million people who die of malaria every year, most of them are African children under five years old. Hundreds of millions more people suffer the effects of the mosquito-borne, parasitic disease each year. Scientists have been working for years to develop a preventive malaria vaccine and have recently demonstrated that such a vaccine is possible.

While the approach of much malaria vaccine research and development has centered on using one or more components of the malaria parasite that the human immune system can recognize, Sanaria is focused on using an attenuated, or weakened, form of the whole parasite. The idea is that when this attenuated parasite is given to individuals, they will become immune to malaria but will not get sick. This is the first vaccine candidate of its kind in the MVI portfolio.<
'"/>


14-Dec-2006


Page: 1 2

Related biology news :

1. Malaria -- Effective insecticide-repellent synergy against mosquito vectors
2. Malaria-resistant mosquitoes battle disease with molecular warhead
3. Malaria and Epstein-Barr virus linked to pediatric cancer in Africa
4. Malaria in pregnancy: What can the social sciences contribute?
5. Malaria: The right vaccine in the right place?
6. 20 Years of Malaria Research: Outcomes and Perspectives
7. Malaria poses additional risks for first-time mothers
8. Malaria drug may treat metabolic syndromes many symptoms
9. Malaria: Efficacy of monotherapies in Cameroon
10. Malaria, potato famine pathogen share surprising trait
11. Malaria parasite impairs key immune system cells

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:7/18/2020)... , ... July 17, 2020 , ... Commercial launch readiness ... pharma’s ability to discover a COVID cure or vaccine, the global economic downturn will ... price pressure is not going away and capturing full value from every product launch ...
(Date:7/2/2020)... ... July 02, 2020 , ... ... B.V. (MBS) has announced a publication detailing the use of its revolutionary ... polymerase chain reaction (RT-PCR) in 16 minutes. The article, titled "Ultra-fast one-step ...
(Date:6/25/2020)... ... June 24, 2020 , ... ... software and software-driven clinical data services that accelerate drug development, is collaborating with ... an XPO1 inhibitor, in hospitalized patients with severe COVID-19. This is the first ...
Breaking Biology News(10 mins):
(Date:7/18/2020)... , ... July 16, 2020 , ... ... to aid in the early detection and prevention of high-burden diseases, and Centric ... US-based hospitals and healthcare organizations to utilize existing data in order to identify ...
(Date:7/10/2020)... ... July 09, 2020 , ... ... that Massachusetts Institute of Technology (MIT) has expanded the company’s exclusive license ... to move into the point-of-care diagnostic market, focusing initially on the SARS-CoV-2 ...
(Date:7/7/2020)... ... July 06, 2020 , ... R3 International is now offering stem ... 200 million stem cells. Depending on the patient's condition, treatment may be offered IV, ... die having some form of Alzheimers dementia, and the incidence continues to increase as ...
(Date:7/1/2020)... ... June 29, 2020 , ... ... competitively procured purchasing contracts to its membership, recently named BioFit Engineered Products ... with the opportunity to purchase ergonomic seating, cafeteria tables, book trucks and carts ...
Breaking Biology Technology:
Cached News: